Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[1][2][3][4] A phase 1 clinical trial comparing MDMA, MDA, Lys-MDMA, and Lys-MDA has been completed as of August 2024.[5]
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C16H25N3O3 |
| Molar mass | 307.394 g·mol−1 |
| 3D model (JSmol) | |
| |
See also
editReferences
edit- ^ Buntz B (21 September 2022). "MindMed announces Phase 1 study of MDMA-like substances". Drug Discovery and Development.
- ^ "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances". Biospace.com. 20 September 2022.
- ^ WO 2022/053696, Grill M, "Novel Safrylamine derivatives having prodrug properties.", published 17 March 2022, assigned to Compass Pathfinder Limited.
- ^ WO 2023/283373, Clark S, Duncton MA, "Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof", published 12 January 2023, assigned to Terran Biosciences Inc.
- ^ "ClinicalTrials.gov". ClinicalTrials.gov. Retrieved 13 November 2024.